Financials data is unavailable for this security.
View more
Year on year Eurobio Scientific SA 's revenues fell -14.81% from 152.61m to 130.00m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 24.94m to 4.84m, a -80.61% decrease.
Gross margin | 47.11% |
---|---|
Net profit margin | 3.72% |
Operating margin | 6.69% |
Return on assets | 1.49% |
---|---|
Return on equity | 2.78% |
Return on investment | 1.80% |
More ▼
Cash flow in EURView more
In 2023, Eurobio Scientific SA did not generate a significant amount of cash. However, the company earned 26.77m from its operations for a Cash Flow Margin of 20.59%. In addition the company used 318.00k on investing activities and also paid 23.50m in financing cash flows.
Cash flow per share | 1.60 |
---|---|
Price/Cash flow per share | 14.22 |
Book value per share | 16.02 |
---|---|
Tangible book value per share | 2.00 |
More ▼
Balance sheet in EURView more
Current ratio | 2.72 |
---|---|
Quick ratio | 2.32 |
Total debt/total equity | 0.5788 |
---|---|
Total debt/total capital | 0.3666 |
More ▼
Growth rates in EUR
Year on year, growth in earnings per share excluding extraordinary items dropped -82.27%.
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | -82.18 |